While around 75% of therapies in the market are based on antibodies and the classical way of purifying them in the bed chromatography approach. This method of purification is only good for a product with a long shelf-life or is in high demand. What about the products with low demand or are only for therapeutic and clinical use?
Siddhartha Shrivastava, Ph.D., Senior Scientist, Downstream Process Development, Patheon says “if the product has got a long shelf-life, a long demand, that makes sense for us to invest in it and create a good infrastructure, a good footprint and bear the high operational and capital expenditure. But, if the product is in the development phase and you need to have some quick lots of drugs so that we can try clinically, that does not make sense. And, by moving to the disposable technology we are also reducing the chances of cross contamination.”
In this podcast interview, Dr. Siddhartha Shrivastava explains:
• Why disposable technology is more appealing compared to conventional technology
• The cost effectiveness of disposable technology
• Large scale testing of disposable membrane chromatography systems
Listen to the podcast or download a transcript here!
Editor’s note: Interested in learning more about the importance of disposable membrane chromatography systems for mAb purification? Then join us for BPI West, March 14-17th in Oakland, CA.
Download the event agenda or visit the event website.
Save $400 - Register with the code BPIWEST16BL
|
Share this article with your social network, just click below to share now!
|
|
|
No comments :
Post a Comment